567 related articles for article (PubMed ID: 18339861)
21. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
22. Ligand-induced dimerization of the extracellular domain of the TGF-beta receptor type II.
Letourneur O; Goetschy JF; Horisberger M; Grütter MG
Biochem Biophys Res Commun; 1996 Jul; 224(3):709-16. PubMed ID: 8713111
[TBL] [Abstract][Full Text] [Related]
23. Transforming growth factor beta receptor type II inactivation induces the malignant transformation of intestinal neoplasms initiated by Apc mutation.
Muñoz NM; Upton M; Rojas A; Washington MK; Lin L; Chytil A; Sozmen EG; Madison BB; Pozzi A; Moon RT; Moses HL; Grady WM
Cancer Res; 2006 Oct; 66(20):9837-44. PubMed ID: 17047044
[TBL] [Abstract][Full Text] [Related]
24. A delicate balance: TGF-beta and the tumor microenvironment.
Stover DG; Bierie B; Moses HL
J Cell Biochem; 2007 Jul; 101(4):851-61. PubMed ID: 17486574
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of transforming growth factor-beta signaling pathway in the wall of normal and varicose veins.
Kowalewski R; Malkowski A; Sobolewski K; Gacko M
Pathobiology; 2010; 77(1):1-6. PubMed ID: 20185961
[TBL] [Abstract][Full Text] [Related]
26. Expression of a dominant negative type II TGF-beta receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development.
Amendt C; Schirmacher P; Weber H; Blessing M
Oncogene; 1998 Jul; 17(1):25-34. PubMed ID: 9671311
[TBL] [Abstract][Full Text] [Related]
27. Enhanced hepatocyte growth factor signaling by type II transforming growth factor-beta receptor knockout fibroblasts promotes mammary tumorigenesis.
Cheng N; Chytil A; Shyr Y; Joly A; Moses HL
Cancer Res; 2007 May; 67(10):4869-77. PubMed ID: 17495323
[TBL] [Abstract][Full Text] [Related]
28. Lack of transforming growth factor-β signaling promotes collective cancer cell invasion through tumor-stromal crosstalk.
Matise LA; Palmer TD; Ashby WJ; Nashabi A; Chytil A; Aakre M; Pickup MW; Gorska AE; Zijlstra A; Moses HL
Breast Cancer Res; 2012 Jul; 14(4):R98. PubMed ID: 22748014
[TBL] [Abstract][Full Text] [Related]
29. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism.
Van Aarsen LA; Leone DR; Ho S; Dolinski BM; McCoon PE; LePage DJ; Kelly R; Heaney G; Rayhorn P; Reid C; Simon KJ; Horan GS; Tao N; Gardner HA; Skelly MM; Gown AM; Thomas GJ; Weinreb PH; Fawell SE; Violette SM
Cancer Res; 2008 Jan; 68(2):561-70. PubMed ID: 18199553
[TBL] [Abstract][Full Text] [Related]
30. Mouse models of transforming growth factor beta impact in breast development and cancer.
Serra R; Crowley MR
Endocr Relat Cancer; 2005 Dec; 12(4):749-60. PubMed ID: 16322320
[TBL] [Abstract][Full Text] [Related]
31. Conditional deletion of the TGF-beta type II receptor in Col2a expressing cells results in defects in the axial skeleton without alterations in chondrocyte differentiation or embryonic development of long bones.
Baffi MO; Slattery E; Sohn P; Moses HL; Chytil A; Serra R
Dev Biol; 2004 Dec; 276(1):124-42. PubMed ID: 15531369
[TBL] [Abstract][Full Text] [Related]
32. Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression.
Boulanger CA; Wagner KU; Smith GH
Oncogene; 2005 Jan; 24(4):552-60. PubMed ID: 15580303
[TBL] [Abstract][Full Text] [Related]
33. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression.
Corsino P; Davis B; Law M; Chytil A; Forrester E; Nørgaard P; Teoh N; Law B
Cancer Res; 2007 Apr; 67(7):3135-44. PubMed ID: 17409420
[TBL] [Abstract][Full Text] [Related]
34. Transforming growth factor-beta receptor inhibition enhances adenoviral infectability of carcinoma cells via up-regulation of Coxsackie and Adenovirus Receptor in conjunction with reversal of epithelial-mesenchymal transition.
Lacher MD; Tiirikainen MI; Saunier EF; Christian C; Anders M; Oft M; Balmain A; Akhurst RJ; Korn WM
Cancer Res; 2006 Feb; 66(3):1648-57. PubMed ID: 16452224
[TBL] [Abstract][Full Text] [Related]
35. alpha2HS-glycoprotein, an antagonist of transforming growth factor beta in vivo, inhibits intestinal tumor progression.
Swallow CJ; Partridge EA; Macmillan JC; Tajirian T; DiGuglielmo GM; Hay K; Szweras M; Jahnen-Dechent W; Wrana JL; Redston M; Gallinger S; Dennis JW
Cancer Res; 2004 Sep; 64(18):6402-9. PubMed ID: 15374947
[TBL] [Abstract][Full Text] [Related]
36. Understanding mammary gland development through the imbalanced expression of growth regulators.
Robinson GW; Smith GH; Gallahan D; Zimmer A; Furth PA; Hennighausen L
Dev Dyn; 1996 Jun; 206(2):159-68. PubMed ID: 8725283
[TBL] [Abstract][Full Text] [Related]
37. A crucial role of caspase-3 in osteogenic differentiation of bone marrow stromal stem cells.
Miura M; Chen XD; Allen MR; Bi Y; Gronthos S; Seo BM; Lakhani S; Flavell RA; Feng XH; Robey PG; Young M; Shi S
J Clin Invest; 2004 Dec; 114(12):1704-13. PubMed ID: 15599395
[TBL] [Abstract][Full Text] [Related]
38. Tranilast inhibits the growth and metastasis of mammary carcinoma.
Chakrabarti R; Subramaniam V; Abdalla S; Jothy S; Prud'homme GJ
Anticancer Drugs; 2009 Jun; 20(5):334-45. PubMed ID: 19322072
[TBL] [Abstract][Full Text] [Related]
39. Transforming growth factor beta receptor type II inactivation promotes the establishment and progression of colon cancer.
Biswas S; Chytil A; Washington K; Romero-Gallo J; Gorska AE; Wirth PS; Gautam S; Moses HL; Grady WM
Cancer Res; 2004 Jul; 64(14):4687-92. PubMed ID: 15256431
[TBL] [Abstract][Full Text] [Related]
40. Chemical enhancers of cytokine signaling that suppress microfilament turnover and tumor cell growth.
Park HJ; Partridge E; Cheung P; Pawling J; Donovan R; Wrana JL; Dennis JW
Cancer Res; 2006 Apr; 66(7):3558-66. PubMed ID: 16585180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
